Compare · AGMB vs ARGX
AGMB vs ARGX
Side-by-side comparison of AgomAb Therapeutics NV (AGMB) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGMB and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.76B, about 107.9x AGMB ($507.7M).
- Over the past year, AGMB is down 30.5% and ARGX is up 51.2% - ARGX leads by 81.7 points.
- ARGX has been more active in the news (5 items in the past 4 weeks vs 2 for AGMB).
- ARGX has more recent analyst coverage (25 ratings vs 3 for AGMB).
- Company
- AgomAb Therapeutics NV
- argenx SE
- Price
- $10.57+3.12%
- $882.63-1.03%
- Market cap
- $507.7M
- $54.76B
- 1M return
- -9.42%
- +12.11%
- 1Y return
- -30.47%
- +51.24%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- 2017
- News (4w)
- 2
- 5
- Recent ratings
- 3
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest AGMB
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Announces Results of Annual General Meeting
- SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
- SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
- Agomab to Participate in Upcoming Conferences
- SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
- SEC Form 6-K filed by AgomAb Therapeutics NV
- Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
- SEC Form 20-F filed by AgomAb Therapeutics NV
- SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference